Eagle's medium (DMEM, Invitrogen, Carlsbad, CA) with phenol red buffered with HEPES and supplemented with 10% v/v fetal bovine serum (FBS), 1% L-glutamine, and 100 U/ml penicillin/streptomycin. HeLa-luc cells were also supplemented with 100 µg/ml of G418. WT and hsf-1-/-MEFs were maintained on DMEM supplemented with 10% FBS, 0.1 mM nonessential amino acids, 100 U/ml penicillin/streptomycin, and 55 µM 2-mercaptoethanol. HttQ74-GFP PC12 cells were previously described 3 and were maintained on DMEM supplemented with 5% v/v Tet-approved FBS, 10% v/v horse serum, 100 µg/ml G418, 75 µg/ml hygromycin B, and 100 U/ml penicillin/streptomycin.
Cells co-expressing ΔF508-CFTR and CFBE41o--YFP were grown in α-MEM containing 100 U/ml penicillin/streptomycin, 10% v/v FBS, 2 mM L-glutamine, 2 µg/ml puromycin and 0.75 mg/ml G418. Cells were maintained at 37 o C with 5% CO 2 atmosphere until they were ready for passage or harvest.
Cell-based High-throughput Assays. The automated primary screens were performed according to the following steps. For the 100,000 compound library screened at the Southern Research Institute, the assay was optimized for a 384-well plate format and resulted in a Z'-value >0.6 using CdCl 2 as positive control (50 µM). HeLa-luc cells were dispensed into white tissue culture treated 384-well plates at a density of 1,875 cells/well in 20 µL assay medium using a WellMate with a small bore cassette head (Matrix Technologies Corp., Thermo Fisher Scientific, Hudson, NH). The assay plates were incubated for 16-18 hours at 37 o C and 5% CO 2 before compound addition.
Compound addition was performed in a two step process with the positive control added to control wells and an equal volume of medium added to remaining wells with a Biomek FX liquid handling system (Beckman Coulter Inc., Brea, CA). The compounds were then delivered without dilution in 50 nL with 5 µL medium at a concentration of 2 µg/mL using an Echo 550 liquid handler (Labcyte Inc., Sunnyvale, CA). After 24 h incubation with compounds, the assay plates were equilibrated to room temperature before endpoint addition. 25 µl of Bright-Glo Luciferase Assay System (Promega, Madison, WI) was added to the plates using a Multidrop dispenser (Titertek Instruments Inc., Huntsville, AL) and luminescence signal was read using an Envision multi-label plate reader (Perkin Elmer, Waltham, MA). The assay was run in three 107-plate batches run in serial.
Every step of the assay process, along with every reagent and instrument used throughout the assay process was tracked using a Uniflow Laboratory Information Management System to ensure consistency between screening runs and to facilitate any trouble shooting that may arise along the way. Following each screening batch, data was imported into IDBS ActivityBase data management system. Because of the low hit rate and the relatively low response elicited by the library compounds when compared to the response to CdCl 2 , the hit criteria was defined as >5% signal induction of the positive control. Using this criterion, 37 compounds were identified as hits (0.04% hit rate). Dose-response experiments were then performed in triplicate using a 1:2 serial dilution of the hit compounds in DMSO starting from 20 µg/ml. Because of the narrow active concentration range of compounds tested in dose response (data not shown), the list of compounds to be tested in dose response was expanded to 169 based on structural relationships to the hits identified in the primary screen. A detailed description of the protocol used at the SRIMSC is available at the PubChem website (http://pubchem.ncbi.nlm.nih.gov/; PubChem AIDs 1259).
Gel Mobility Shift Analysis (EMSA).
Electrophoretic mobility shift analysis was performed using a 32 P-labeled probe containing the proximal heat shock element from the human Hsp70.1 gene promoter. The whole cell extract-labeled probe mixtures were Cells were stimulated with a final concentration of 10 µM forskolin (fsk) and 50 µM genistein (gen) for 15 min prior to addition of PBS + NaI (replacement of NaCl with 137 mM NaI). Fluorescence was monitored every second for a total of 30 seconds (3 seconds prior to addition of NaI and 27 seconds after addition of NaI). Data were normalized to the initial fluorescence to account for variations in the overall starting fluorescence. To ensure that the observed H148Q/I152L-YFP fluorescence quenching was the result of ΔF508-CFTR activation and not the action of additional halide channels, the CFTR specific inhibitor (CFInh-172) was used.
ΔF508-CFTR Transport Assay. CFBE41o-cells stably expressing ΔF508-CFTR
were plated in 12-well dishes and grown to confluency in growth media (α-MEM containing 100 U/ml penicillin, 100 U/ml streptomycin, 10% v/v FBS, 2 mM L-glutamine and 2 µg/ml puromycin). Cells were treated with the indicated concentration of compound in complete growth media and maintained at 37 o C, 5% CO 2 for 24 hrs. Cells Proteasome Inhibition Assay. The assay was essentially performed as described by Kisselev et al. 15 . In brief, HeLa cells were incubated with either DMSO (negative control), the positive controls MG132 (10 µM) and lactacystin (6 µM) or the PRs A1, A3
and F1 for 3 and 6 hours and then harvested. Cells were lysed in homogenization buffer 
